Considering these discussions to constitute the most appropriate individual approach for low metastatic burden disease, we searched for an answer whether Ga-68 PSMA PET/CT scanning is adequate to predict intermediate risk, high risk, or oligometastatic PCa as an initial staging modality in this study (Figure 3). This evidence concerns the gene FOLH1 and posterior cortical atrophy.